TOYOPEARL PPG-600M: the HIC resin for the purification of ADCs
contributed by Tosoh |
Antibody-drug conjugates (ADCs) are promising anticancer biopharmaceuticals with one of the highest annual growth rates. Four ADCs received market approval to this point. They combine the high selectivity and affinity of an antibody to cancer cells with the toxicity of chemotherapeutics in one molecule.
ADCs consist of a monoclonal antibody, covalently bound via a linker to a highly potent cytotoxic drug. Due to the highly toxic payload, very high safety standards should be implemented during method and process development. ADC-mimic contain a non-toxic payload with similar structure and physicochemical properties as the toxic payload of an ADC. Therefore, they can be used as a model to develop a suitable purification process or analytical method. The ADC-mimic in this work consists of Adalimumab bound to Fluorescein 5-isocyanate (FITC).
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.